GlassScriptPhysician profile
Jordan Kim
NPI 1922461698
$1,753.35
in general payments reported to CMS, 2019-2025
16 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.80 · 2020: $111 · 2021: $559 · 2022: $363 · 2023: $563 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $695.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $601.72 | 2020-2025 | |
| Novo Nordisk INC | $217.70 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $212.38 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $126.96 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.94 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.57 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $77.98 | 2021-2022 | |
| Pfizer INC. | $76.09 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $67.79 | 2021-2023 | Farxiga |
| Amgen INC. | $60.53 | 2019-2023 | Otezla, Repatha |
| Abbott Laboratories | $39.47 | 2023 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.14 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $25.26 | 2023 | Nuedexta |
| Alkermes, INC. | $18.61 | 2021 | |
| Antares Pharma, INC. | $14.47 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.